7,548.02

-172.37

-2.23%

51,692.13

-650.43

-1.24%

25,261.09

-923.63

-3.53%

2,797.39

-61.82

-2.16%

4.9410

-0.0480

-0.96%

22.03

+4.83

+28.07%

3,892.20

-139.20

-3.45%

76,820.72

-3,941.53

-4.88%

Crude Oil Dec 26

104.85

+2.85

+2.79%

US Private Equity

10,932.82

-7.68

-0.07%

NasdaqGS - Nasdaq Real Time Price USD

Vaxcyte, Inc. (PCVX)

61.85 -0.76 (-1.21%)

As of 2:16:19 PM EDT. Market Open.

Trade Vaxcyte on Coinbase

Loading Chart for PCVX

Chart Range Bar

Interval:

In partnership with ChartIQ

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet

Why Vaxcyte (PCVX) Is Getting Attention Again

Why Vaxcyte (PCVX) Is Getting Attention Again

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)

As Expected: Vaxcyte Announces $1 Billion Stock and Convertible Raise a Day After Its Phase 3 Win (and Sinks 10%)

Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results

Vaxcyte VAX-31 pneumococcal vaccine phase 3 trial results

Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

Vaxcyte’s VAX-31 Meets All Primary Endpoints in Pivotal Phase III OPUS-1 Trial

NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test

NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case

Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck

Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck

Mobilize your Website

View Site in Mobile | Classic

Share by: